U.S. Department of Health and Human Services Office of Disease Prevention and Health Promotion

Update to U.S. Selected Practice Recommendations for Contraceptive Use: Self-Administration of Subcutaneous Depot Medroxyprogesterone Acetate

About this resource:

Non-Systematic Review

Source: Centers for Disease Control and Prevention

Last Reviewed: May 2021

Workgroups: Family Planning Workgroup

In this update to the U.S. Selected Practice Recommendations for Contraceptive Use, the Centers for Disease Control and Prevention (CDC) recommends making self-administered subcutaneous depot medroxyprogesterone acetate (DMPA-SC) available as an additional approach to deliver injectable contraception.

DMPA-SC is a method of birth control that is given under the skin, usually every 3 months. CDC found that self-administered DMPA-SC might improve access to contraception by removing barriers, like in-person visits to a health care provider, while promoting empowerment through self-care.

Read more about this resource

Objectives related to this resource (2)

Increase the proportion of women at risk for unintended pregnancy who use effective birth control — FP‑10
Little or no detectable change
Increase the proportion of adolescent females at risk for unintended pregnancy who use effective birth control — FP‑11
Little or no detectable change

Suggested Citation

1.

Curtis KM, Nguyen A, Reeves JA, Clark EA, Folger SG, Whiteman MK. (2021). Update to U.S. Selected Practice Recommendations for Contraceptive Use: Self-Administration of Subcutaneous Depot Medroxyprogesterone Acetate. Retrieved from https://www.cdc.gov/mmwr/volumes/70/wr/mm7020a2.htm?s_cid=mm7020a2_w.